DK2201012T3 - Pyrrolo[2,3-d]pyrimidinderivater som proteinkinase b-hæmmere - Google Patents

Pyrrolo[2,3-d]pyrimidinderivater som proteinkinase b-hæmmere

Info

Publication number
DK2201012T3
DK2201012T3 DK08806741.8T DK08806741T DK2201012T3 DK 2201012 T3 DK2201012 T3 DK 2201012T3 DK 08806741 T DK08806741 T DK 08806741T DK 2201012 T3 DK2201012 T3 DK 2201012T3
Authority
DK
Denmark
Prior art keywords
proteinkinase
pyrrolo
inhibitors
pyrimidine derivatives
pyrimidine
Prior art date
Application number
DK08806741.8T
Other languages
English (en)
Inventor
Zbigniew Stanley Matusiak
Jeffrey James Morris
Paul David Johnson
Andrew Leach
Richard William Arthur Luke
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40251789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2201012(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK2201012T3 publication Critical patent/DK2201012T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
DK08806741.8T 2007-10-11 2008-10-09 Pyrrolo[2,3-d]pyrimidinderivater som proteinkinase b-hæmmere DK2201012T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97919207P 2007-10-11 2007-10-11
US4786208P 2008-04-25 2008-04-25
PCT/GB2008/050925 WO2009047563A1 (en) 2007-10-11 2008-10-09 Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors

Publications (1)

Publication Number Publication Date
DK2201012T3 true DK2201012T3 (da) 2014-09-08

Family

ID=40251789

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08806741.8T DK2201012T3 (da) 2007-10-11 2008-10-09 Pyrrolo[2,3-d]pyrimidinderivater som proteinkinase b-hæmmere

Country Status (38)

Country Link
US (8) US8101623B2 (da)
EP (1) EP2201012B1 (da)
JP (2) JP4705695B2 (da)
KR (1) KR101494734B1 (da)
CN (1) CN101861321B (da)
AR (1) AR068846A1 (da)
AU (1) AU2008309383B2 (da)
BR (1) BRPI0818533B8 (da)
CA (1) CA2701057C (da)
CL (1) CL2008003023A1 (da)
CO (1) CO6270328A2 (da)
CR (1) CR11359A (da)
CU (1) CU23886B1 (da)
CY (1) CY1116929T1 (da)
DK (1) DK2201012T3 (da)
DO (1) DOP2010000103A (da)
EA (1) EA018512B1 (da)
ES (1) ES2522365T3 (da)
GT (1) GT201000082A (da)
HK (1) HK1143154A1 (da)
HN (1) HN2010000653A (da)
HR (1) HRP20140807T1 (da)
IL (1) IL204721A (da)
ME (1) ME01999B (da)
MX (1) MX2010003927A (da)
MY (1) MY150059A (da)
NI (1) NI201000050A (da)
NZ (1) NZ585261A (da)
PE (2) PE20090964A1 (da)
PL (1) PL2201012T3 (da)
PT (1) PT2201012E (da)
RS (1) RS53552B1 (da)
SA (1) SA08290625B1 (da)
SI (1) SI2201012T1 (da)
TW (1) TWI453021B (da)
UY (1) UY31384A1 (da)
WO (1) WO2009047563A1 (da)
ZA (1) ZA201002318B (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
DK3421471T3 (da) 2006-04-25 2021-06-14 Astex Therapeutics Ltd Purin- og deazapurinderivater som farmaceutiske forbindelser
JP5339291B2 (ja) 2006-08-10 2013-11-13 オンコセラピー・サイエンス株式会社 乳癌に関連する遺伝子およびポリペプチド
TWI453021B (zh) 2007-10-11 2014-09-21 Astrazeneca Ab 新穎蛋白質激酶ｂ抑制劑
WO2011002772A1 (en) * 2009-06-29 2011-01-06 Oncotherapy Science, Inc. Imidazopyridine derivatives and pbk inhibitors containing the same
GB201020161D0 (en) 2010-11-26 2011-01-12 Almac Discovery Ltd Pharmaceutical compounds
US9045485B2 (en) 2010-12-16 2015-06-02 Convergence Pharmaceuticals Limited ASK 1 inhibiting pyrrolopyrimidine derivatives
JP6100700B2 (ja) 2011-01-11 2017-03-22 ノバルティス アーゲー 組合せ
LT2694056T (lt) 2011-04-01 2019-12-10 Astrazeneca Ab Terapinis gydymas
AU2013205648B2 (en) * 2011-11-30 2015-02-05 Astrazeneca Ab Combination treatment
JP6309454B2 (ja) * 2011-11-30 2018-04-11 アストラゼネカ アクチボラグ 癌の併用処置
AU2013204533B2 (en) * 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
RU2644769C2 (ru) 2013-01-23 2018-02-14 Астразенека Аб Химические соединения
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
US9993460B2 (en) 2013-07-26 2018-06-12 Race Oncology Ltd. Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
JP6295578B2 (ja) * 2013-09-30 2018-03-20 凸版印刷株式会社 反応容器、核酸解析装置、および核酸解析方法
JP2016531884A (ja) * 2013-10-01 2016-10-13 ノバルティス アーゲー 組合せ物
CR20200362A (es) 2014-02-13 2020-10-26 Incyte Corp CICLOPROPILAMINA COMO INHIBIDORES DE LA LSD1 (Divisional 2016-0395)
US9670210B2 (en) 2014-02-13 2017-06-06 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
WO2015123408A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
MY173661A (en) * 2014-05-28 2020-02-14 Astrazeneca Ab Processes for the preparation of azd5363 and novel intermediate used therein
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
CN107660205B (zh) 2015-04-03 2021-08-27 因赛特公司 作为lsd1抑制剂的杂环化合物
EP3334709A1 (en) 2015-08-12 2018-06-20 Incyte Corporation Salts of an lsd1 inhibitor
TW201726140A (zh) 2015-09-17 2017-08-01 瑞典商阿斯特捷利康公司 治療癌症之新型生物標記及方法
PE20190377A1 (es) 2016-04-22 2019-03-08 Incyte Corp Formulaciones de un inhibidor de lsd 1
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
MX2022005250A (es) 2019-11-04 2022-06-08 Astrazeneca Ab Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b.
US20240051964A1 (en) * 2021-01-04 2024-02-15 Teva Pharmaceuticals International Gmbh Solid state forms of capivasertib and process for preparation thereof
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
CN114601836B (zh) * 2022-04-12 2022-12-06 四川大学华西医院 一种akt抑制剂在制备治疗乳腺癌的药物中的应用

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637271A (da) 1963-04-04 1900-01-01
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
AU715202B2 (en) 1996-04-03 2000-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP0961780B1 (en) 1997-02-12 2007-04-11 Electrophoretics Limited Protein markers for lung cancer and use thereof
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US6187778B1 (en) 1997-08-05 2001-02-13 Pfizer Inc. 4-aminopyrrole (3, 2-D) pyrimidines as neuropeptide Y receptor antagonists
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
IL139811A0 (en) 1998-06-04 2002-02-10 Abbott Lab Cell adhesion-inhibiting antinflammatory compounds
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
PT1154774E (pt) 1999-02-10 2005-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de angiogenese
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
DK1676845T3 (da) 1999-11-05 2008-09-15 Astrazeneca Ab Nye quinazolinderivater
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
ATE369359T1 (de) 2000-02-15 2007-08-15 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
CA2406979A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
ATE423120T1 (de) 2000-06-26 2009-03-15 Pfizer Prod Inc Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
MXPA03001777A (es) 2000-08-31 2003-06-04 Hoffmann La Roche Derivados de quinazolina como antagonistas adrenergicos alfa-1.
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
BR0115847A (pt) 2000-12-01 2004-02-25 Osi Pharm Inc Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
EP1390353A1 (en) * 2001-04-27 2004-02-25 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
EP1474425B9 (en) 2002-01-07 2008-07-02 Eisai Co., Ltd. Deazapurines and uses thereof
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
EP1522314B1 (en) 2002-06-26 2014-03-05 Ono Pharmaceutical Co., Ltd. Remedies for diseases caused by vascular contraction or dilation
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US20050288503A1 (en) 2002-09-06 2005-12-29 Adams Jerry L Novel compounds
WO2004043380A2 (en) 2002-11-08 2004-05-27 President And Fellows Of Harvard College Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors
MXPA05005983A (es) 2002-12-04 2005-08-18 Eisai Co Ltd Compuestos de anillo fusionado 1,3-dihidroimidazol.
EP1444982A1 (de) 2003-02-06 2004-08-11 Merckle Gmbh Verwendung von Purinderivaten als selektive Kinase-Inhibitoren
EP1601357A4 (en) 2003-03-10 2007-10-03 Schering Corp HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS
CA2507893A1 (en) 2003-04-21 2004-11-04 Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky (purin-6-yl) amino acid and production method thereof
FR2856685B1 (fr) 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
AU2004268621C1 (en) 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
EP1684694A2 (en) 2003-11-21 2006-08-02 Array Biopharma, Inc. Akt protein kinase inhibitors
EP1698375B1 (en) 2003-12-25 2014-04-02 Ono Pharmaceutical Co., Ltd. Azetidine ring compounds and drugs comprising the same
RU2006138036A (ru) * 2004-03-30 2008-05-10 Чирон Корпорейшн (Us) Производные замещенного тиофена в качестве противораковых средств
AU2005249380C1 (en) * 2004-04-23 2012-09-20 Exelixis, Inc. Kinase modulators and methods of use
MY179032A (en) * 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
EP1848719B1 (en) * 2004-12-28 2012-02-01 Exelixis, Inc. [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
FR2880540B1 (fr) 2005-01-13 2008-07-11 Aventis Pharma Sa Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90
FR2880626B1 (fr) 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
WO2006091450A1 (en) 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
US20060281768A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
JP5071374B2 (ja) 2005-07-14 2012-11-14 アステラス製薬株式会社 ヘテロ環ヤヌスキナーゼ３阻害剤
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
WO2007084667A2 (en) 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Fused heterobicyclic kinase inhibitors
US20090082370A1 (en) 2006-04-25 2009-03-26 Neil Thomas Thompson Pharmaceutical Combinations of PK Inhibitors and Other Active Agents
DK3421471T3 (da) 2006-04-25 2021-06-14 Astex Therapeutics Ltd Purin- og deazapurinderivater som farmaceutiske forbindelser
EP2016077A2 (en) 2006-04-25 2009-01-21 Astex Therapeutics Limited Pharmaceutical compounds
WO2007125325A1 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
JP2009534454A (ja) 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
AR064416A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
EP2124951B1 (en) 2006-12-21 2014-05-21 Vertex Pharmaceuticals Inc. 5-cyan0-4- (pyrrolo[2, 3b]pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
AR064415A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
TWI453021B (zh) 2007-10-11 2014-09-21 Astrazeneca Ab 新穎蛋白質激酶ｂ抑制劑

Also Published As

Publication number Publication date
CU23886B1 (es) 2013-04-19
CA2701057A1 (en) 2009-04-16
PE20090964A1 (es) 2009-08-15
KR101494734B1 (ko) 2015-02-26
HRP20140807T1 (hr) 2014-11-21
IL204721A0 (en) 2010-11-30
EA201000552A1 (ru) 2010-12-30
PE20130152A1 (es) 2013-03-17
PT2201012E (pt) 2014-09-04
HK1143154A1 (en) 2010-12-24
CR11359A (es) 2010-07-15
CY1116929T1 (el) 2017-04-05
NZ585261A (en) 2011-10-28
US20200239483A1 (en) 2020-07-30
NI201000050A (es) 2011-12-22
SA08290625B1 (ar) 2012-02-12
TW200927128A (en) 2009-07-01
SI2201012T1 (sl) 2014-10-30
JP2011157364A (ja) 2011-08-18
US20240109902A1 (en) 2024-04-04
HN2010000653A (es) 2013-03-18
US20120190679A1 (en) 2012-07-26
EA018512B1 (ru) 2013-08-30
BRPI0818533B1 (pt) 2020-12-01
ES2522365T3 (es) 2014-11-14
ME01999B (me) 2015-05-20
CN101861321B (zh) 2013-02-06
BRPI0818533A2 (pt) 2017-06-06
CN101861321A (zh) 2010-10-13
US20170057969A1 (en) 2017-03-02
WO2009047563A1 (en) 2009-04-16
PL2201012T3 (pl) 2014-11-28
US9492453B2 (en) 2016-11-15
JP4705695B2 (ja) 2011-06-22
EP2201012A1 (en) 2010-06-30
US20220220116A1 (en) 2022-07-14
ZA201002318B (en) 2012-09-26
US11236095B2 (en) 2022-02-01
US11760760B2 (en) 2023-09-19
US20150182531A1 (en) 2015-07-02
MX2010003927A (es) 2010-04-30
DOP2010000103A (es) 2010-05-31
UY31384A1 (es) 2009-05-29
AU2008309383A1 (en) 2009-04-16
CO6270328A2 (es) 2011-04-20
JP5330430B2 (ja) 2013-10-30
US8101623B2 (en) 2012-01-24
IL204721A (en) 2013-10-31
EP2201012B1 (en) 2014-06-25
CA2701057C (en) 2015-03-24
US10059714B2 (en) 2018-08-28
US20180312516A1 (en) 2018-11-01
CU20100062A7 (es) 2011-10-05
JP2011500547A (ja) 2011-01-06
TWI453021B (zh) 2014-09-21
US10654855B2 (en) 2020-05-19
US20090163524A1 (en) 2009-06-25
AR068846A1 (es) 2009-12-09
RS53552B1 (en) 2015-02-27
AU2008309383B2 (en) 2012-04-19
MY150059A (en) 2013-11-29
GT201000082A (es) 2015-03-10
KR20100101077A (ko) 2010-09-16
BRPI0818533B8 (pt) 2021-05-25
CL2008003023A1 (es) 2009-11-27

Similar Documents

Publication Publication Date Title
DK2201012T3 (da) Pyrrolo[2,3-d]pyrimidinderivater som proteinkinase b-hæmmere
LTC3106463I2 (lt) Pakeistieji pirazolo[1,5-a]pirimidino junginiai kaip trk kinazės slopikliai
DK2384326T3 (da) Pyrrolo[2,3-d]pyrimidinforbindelser
DK2137184T3 (da) Imidazo[1,2-a]pyridinforbindelser som receptor-tyrosinkinaseinhibitorer
BRPI0814254A2 (pt) Sais do inibidor de janus quinase(r)-3(-4(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-piraz ol-1-il)-3-ciclopentilpropanonitrila
DK2124944T3 (da) Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer
DK1966202T3 (da) Heteroarylsubstituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-d]pyrimidiner som Januskinaseinhibitorer
DK2350075T3 (da) Substituerede imidazo[1,2b]pyridazinforbindelser som trk-kinase-inhibitorer
TWI370127B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
DK2004654T3 (da) Pyrazolopyrimidin derivater til anvendelse som kinase antagonister
SI1893612T1 (sl) Pirolo b piridin derivati kot protein kinazni inhibitorji
DK2118101T3 (da) IMIDAZO (1,5-A)-PYRIDinderivater som glutaminylcyclaseinhibitorer
DK1904494T3 (da) Imidazo[1,2-A]pyridin-forbindelser som VEGF-R2-inhibitorer
IL194755A0 (en) Pyrimidine derivatives as pi3k inhibitors
SMP200800029B (it) 2-ammino-7,8-diidro-6h-pirido[4,3-d]pirimidin-5-oni
DK1763517T3 (da) Pyrimidinderivater som 11beta-HSD1-inhibitorer
DK2220070T3 (da) 2-benzylpyridazinonderivater som Met-kinaseinhibitorer
DE102008005493A8 (de) 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
BRPI0822239A2 (pt) Composto de pirazolo[1,5-a] pirimidina
DK1948661T3 (da) Pyrazolo[4,3-D]pyrimidin-5-YL)-derivat anvendt som PDE5-inhibitorer
DK2167470T3 (da) Triazolo-[1,5A]-chinoliner som adenosin-A3-receptor ligander
BRPI0906985A2 (pt) Derivados de pirido[4,3-d]pirimidinona como inibidores de cinase
TH124152B (th) สารประกอบไพราโซโล[1,5-a]ไพริมิดีนถูกแทนที่ในรูปสารยับยั้ง TRK ไคเนส
ZA200706212B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors